BrainPlotting

ELPEN is the leading Greek pharmaceutical company.
With more than 850 employees, the company ranks 6th among more than 400 companies in the Greek market, with an annual turnover of €150 million (IMS data).

ELPEN has been active in export activities since 1990, with an international presence in more than 60 countries worldwide and a subsidiary in Berlin, Germany, since 2009.
We specialize in branded generics and originator products in CVS, CNS, respiratory, oncology and antimicrobials.

Elpen’s activities include product development, production, regulatory affairs, marketing, sales, and exports. R&D is performed in 1.000m2 facilities focusing on cardiology, endocrinology, cancer, respiratory diseases and OTC. Examples of R&D activities include the Elpenhaler® DPI products already introduced in the EU markets, such as Formopen® (formoterol), Fluticapen® (fluticasone) and Rolenium® (salmeterol/fluticasone combination). We possess full production lines of Oral Solids, Oral Liquids, Dry Powder Inhalation, Injectable, Lyophilized products and a dedicated facility for the production of Oral Solid Penicillin.

NEUROFIT, founded in 1996, is a pre-clinical CRO (Contract Research Organization) based in France and offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes and pain. Neurofit works for major pharmaceutical and Biotech companies in Europe and the USA.
Neurofit’s core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune / inflammatory disorders. Our disease models are clinically relevant and predictive.
Neurofit routinely performs, as part of a study, collection of blood, serum plasma, cerebrospinal fluid as well as dissection of brain microstructures from compound-treated animals to provide customers with useful samples for their pharmacokinetic, biochemistry and immunochemistry analyses.

Crown CRO is a privately owned Finnish CRO founded in 2005. Our headquarters are in Espoo, which is located in Finland’s capital city region. Crown CRO offices are located in Finland, Sweden, Denmark, Norway, Estonia, Latvia and Lithuania. We have ongoing trials managed by our employees in Netherlands, Belgium, UK, Iceland, Ukraine and Belarus. Rest of the Europe and USA we cover through our qualified CRO network.

Our services cover Phase I – IV clinical development from protocol design to final reporting or any parts of the trial in various business models. Data services, Regulatory consulting, Pharmacovigilance, QA, Study Rescue Services and Medical Translation services complete the service package.

Our key therapeutic areas include, but not limited to, CNS, Oncology, Endocrinology, Cardiovascular, Respiratory and Musculoskeletal. We also have strong recent experience in Medical Devices from various indications.

Our passion for research across all our in-house Full-Service functions provide effective and innovative solutions with seamless cooperation for Phase I-III trials in Europe offering special focus on Nordic-Baltic area, together with our own Global Data Services ensuring consistency regardless of where your trials are located, offer you unrivalled customer attention, flexibility and high local level expertise which are key assets you can count on.

See www.crowncro.com for more information.

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support